Humacyte, Inc. (NASDAQ:HUMA) Receives $7.57 Average PT from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $6.4286.

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. BTIG Research lowered their price objective on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen upgraded shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Benchmark raised their target price on shares of Humacyte to $2.00 and gave the stock a “speculative buy” rating in a research note on Monday.

Insiders Place Their Bets

In other news, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius acquired 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. The shares were bought at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the transaction, the director owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Large investors have recently bought and sold shares of the business. Prudential Financial Inc. bought a new stake in Humacyte in the second quarter worth $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter worth $28,000. Truist Financial Corp bought a new stake in Humacyte in the third quarter worth $28,000. Cerity Partners LLC bought a new stake in Humacyte in the second quarter worth $35,000. Finally, Equitable Holdings Inc. bought a new stake in Humacyte in the third quarter worth $29,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Stock Up 1.1%

Shares of NASDAQ HUMA opened at $1.41 on Thursday. The firm has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $1.03. The firm has a market capitalization of $311.94 million, a PE ratio of -2.46 and a beta of 2.45. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. Humacyte has a 12 month low of $0.55 and a 12 month high of $2.93.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. Equities analysts expect that Humacyte will post -0.32 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.